AstraZeneca and Neurimmune Close $760 Million Deal for Cardiomyopathy Antibody Drug | Investor Watch

Join The Conversation! | https://trialsitenews.com/
Alexion, AstraZeneca’s rare diseases group, and Neurimmune announced the closing of an exclusive global collaboration and license agreement for NI006, an investigational human monoclonal antibody currently in phase 1b development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Alexion has been granted an exclusive worldwide license to develop, manufacture and commercialize NI006.